Author: admin

Artificial Intelligence (AI) in Healthcare Market worth $148.4 Billion by 2029, at a CAGR of 48.1%

“Artificial Intelligence (AI) in Healthcare Market”
The global Artificial Intelligence (AI) in Healthcare Market in terms of revenue was estimated to be worth $20.9 billion in 2024 and is poised to reach $148.4 billion by 2029, growing at a CAGR of 48.1% during the forecast period.

The report “Artificial Intelligence (AI) in Healthcare Market by Offering (Hardware, Software, Services), Technology (Machine Learning, Natural Language Processing), Application (Medical Imaging & Diagnostics, Patient Data & Risk Analysis), End User & Region – Global Forecast to 2029” The AI in Healthcare industry is projected to grow from USD 20.9 billion in 2024 and is estimated to reach USD 148.4 billion by 2029; it is expected to grow at a Compound Annual Growth Rate (CAGR) of 48.1% from 2024 to 2029. The growth of the AI in Healthcare industry is driven by the growing need for improvised healthcare services due to the imbalance between the healthcare workforce and patients; improving computing power, and declining hardware cost.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=54679303

Browse 206 market data Tables and 70 Figures spread through 291 Pages and in-depth TOC on “Artificial Intelligence (AI) in Healthcare Market by Offering (Hardware, Software, Services), Technology (Machine Learning, Natural Language Processing), Application (Medical Imaging & Diagnostics, Patient Data & Risk Analysis), End User & Region – Global Forecast to 2029”

View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-healthcare-market-54679303.html

Artificial Intelligence (AI) in Healthcare Market

By offering, the services are projected to grow at a high CAGR of AI in healthcare industry during the forecast period.

AI plays a pivotal role across diverse healthcare applications, necessitating the implementation of sophisticated algorithms for tasks ranging from patient data analysis to drug discovery. Its applications span patient care, risk analysis, lifestyle management, precision medicine, medical imaging, and more. Successful AI deployment hinges on comprehensive services such as deployment, integration, and ongoing support and maintenance. Key players in the AI services in the healthcare industry, including Microsoft, Johnson & Johnson Services, Medtronic, Siemens Healthineers, and Koninklijke Philips, offer a spectrum of support services. These encompass online and offline assistance, installation, training, and post-maintenance, ensuring seamless integration and optimal functioning of AI systems in the dynamic healthcare landscape.

Machine learning technology in AI in healthcare industry is expected to account for the largest share during the forecast period.

Machine learning revolutionizes computing by training systems to learn from data without explicit programming. Instead of predefined instructions, machine learning relies on algorithms to discern patterns and relationships in data, enhancing accuracy and performance with increased exposure to information. Key attributes include data-driven processes, adaptability to new data, and the absence of explicit programming. In healthcare, machine learning intersects with AI, offering transformative applications. It aids in medical diagnosis and imaging by detecting diseases in early stages through image analysis and predicting risks based on electronic health records. Additionally, it accelerates drug discovery, optimizes administrative tasks, and enhances public health initiatives by tracking outbreaks and identifying high-risk individuals. Despite its potential, challenges like data privacy, algorithmic bias, and ethical considerations underscore the importance of careful integration and human oversight in the evolving healthcare landscape shaped by machine learning.

By segment, AI in healthcare industry for Medical Imaging & Diagnostics segment will account for highest CAGR during the forecast period.

AI is reshaping medical imaging and diagnostics, steering in a new era of precision and efficiency. By employing super-resolution techniques, AI reconstructs lower-resolution medical images into highly detailed visuals, aiding in more accurate diagnoses. Automated image analysis and detection capabilities enable AI algorithms to swiftly identify abnormalities, such as tumors or fractures, streamlining the diagnostic process. Moreover, AI’s role in personalized medicine is pivotal, predicting disease risks and treatment responses, and even assisting in surgical planning. This transformative technology enhances the accuracy of diagnoses and contributes to more efficient workflows, improved accessibility to diagnostics, and the potential for personalized treatment strategies.

Asia Pacific will account for the highest CAGR during the forecast period.

The increasing geriatric population in Asia Pacific countries is one of the major drivers for the growth of the AI in healthcare industry. According to the United Nations ESCAP report 2023 a significant demographic shift in Asia and the Pacific, projecting that the older population will surpass 1.3 billion by 2050, doubling from 630 million in 2020. In 2020, 13.6% of the region’s population was aged 60 or above, a figure expected to rise to one-quarter by 2050. According to the National Library of Medicine, 2023. In 2017, the Asia-Pacific region had 9.8% of its total population comprised of older adults. Projections indicate a rise to 13.7% by 2030 and a further increase to 20.3% by 2050. Notably, Japan, China, and Hong Kong are poised to lead globally with the highest percentage of individuals aged 80 and above.

AI in Healthcare Industry: Key players

Key companies operating in the AI in healthcare industry are Koninklijke Philips N.V. (Netherlands), Microsoft (US), Siemens Healthineers AG (Germany), Intel Corporation (US), NVIDIA Corporation (US), Google Inc. (US), GE HealthCare Technologies Inc. (US), Oracle (US), and Johnson & Johnson Services, Inc. (US) among others.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-healthcare-market-54679303.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Artificial Intelligence (AI) in Healthcare Market worth $148.4 Billion by 2029, at a CAGR of 48.1%

Thyroid Cancer Drugs Pipeline 2024 | AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Ta

DelveInsight’s, “Thyroid Cancer Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 51+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Thyroid Cancer Research. Learn more about our innovative pipeline today! @ Thyroid Cancer Pipeline Outlook

 

Key Takeaways from the Thyroid Cancer Pipeline Report

  • August 2024:- Novarits Pharmaceuticals- A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (DTC)
  • DelveInsight’s Thyroid Cancer pipeline report depicts a robust space with 50+ active players working to develop 51+ pipeline therapies for Thyroid Cancer treatment.
  • The leading Thyroid Cancer Companies such as AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
  • Promising Thyroid Cancer Therapies such as Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.

 

Stay informed about the cutting-edge advancements in Thyroid Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Thyroid Cancer Clinical Trials Assessment

 

Thyroid Cancer Emerging Drugs

  • rhTSH: Suzhou Zelgen Biopharmaceuticals

Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the resultant metabolic disturbance, and without the drawbacks associated with the use of bovine TSH. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with thyroid cancer.

  • Nivolumab: Bristol-Myers Squibb

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with thyroid cancer.

  • RX208: Suzhou NeuPharma

RX208 is a potential “best-in-class” BRAF V600E inhibitor with a proprietary novel chemical structure that is different from other marketed BRAF inhibitors. It exhibited high bioavailability and excellent anti-tumor efficacy in preclinical studies. Early clinical data demonstrated preliminary efficacy and good safety and tolerability in patients with cancer, warranting further clinical development. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with thyroid cancer.

  • AIC100: AffyImmune Therapeutics

AffyImmune’s lead product, AIC100, is an affinity-tuned, ICAM-1 targeted, third generation CAR T cell therapy. AIC100’s CAR has an affinity to ICAM-1 similar to the affinity between naturally-occurring T cells and their targets, which is much lower than most CARs used to date and reduces on-target off-tumor toxicities. AIC100 also expresses SSTR2 for real-time monitoring of CAR T cell distribution and activity. Preclinical studies demonstrate that AIC100 induces robust and enduring tumor eradication without toxicity-related relapse or fatality in various solid tumor models. Studies also suggest the potential for combination with anti-PD-1 therapies. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Thyroid Cancer.

 

Learn more about Thyroid Cancer Drugs opportunities in our groundbreaking Thyroid Cancer Research and development projects @ Thyroid Cancer Unmet Needs

 

Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

 

Thyroid Cancer Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

 

Discover the latest advancements in Thyroid Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Thyroid Cancer Market Drivers and Barriers, and Future Perspectives

 

Thyroid Cancer Drugs and Companies

  • Rosiglitazone: Exelixis
  • Lenvatinib: Eisai Limited
  • Ifosfamide: Merck Sharp & Dohme LLC

 

Scope of the Thyroid Cancer Pipeline Report

  • Coverage- 7MM
  • Thyroid Cancer Companies such as AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
  • Thyroid Cancer Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
  • Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Thyroid Cancer Pipeline on our website @ Thyroid Cancer Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Thyroid Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Thyroid Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. rhTSH: Suzhou Zelgen Biopharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Nivolumab: Bristol-Myers Squibb
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AIC100:Affyimmune Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Thyroid Cancer Key Companies
  21. Thyroid Cancer Key Products
  22. Thyroid Cancer- Unmet Needs
  23. Thyroid Cancer- Market Drivers and Barriers
  24. Thyroid Cancer- Future Perspectives and Conclusion
  25. Thyroid Cancer Analyst Views
  26. Thyroid Cancer Key Companies
  27. Appendix 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Thyroid Cancer Drugs Pipeline 2024 | AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Ta

The Decorative Films and Foils Market to Hit USD 3.91 billion by 2029, Innovation of Solar-Powered Advancements Creating Huge Market Expansion – Arizton

“Decorative Films And Foils Market Research Report by Arizton”

According to Arizton’s latest research report, the global decorative films and foils market is growing at a CAGR of 4.52% 2023-2029.    

 

To Know More, Click: https://www.arizton.com/market-reports/decorative-films-and-foils-market 

 

Automotive Industry Gaining Momentum in the Decorative Films and Foils Market 

Decorative films and foils are crucial in enhancing vehicle interiors’ security, privacy, and aesthetics. Installed on the interior surfaces of vehicles, these films contribute to an appealing glossy look and high transparency while ensuring improved passenger or owner privacy. Lighter-tinted car decorative films and foils reduce fading, offer uninterrupted heat rejection, and enhance the overall appearance of a vehicle. Automotive decorative films are valuable in reducing heat loss in winter, gaining solar heat, and maintaining a sustainable and high comfort level inside the vehicle. Furthermore, UV-filtering dyeing films decrease the risk of skin cancer and damage. These films also block more than 90%-95% of Ultraviolet rays, providing more comfort to users by preventing undesirable sun glare. Thus, the ability of automobile decorative films to protect the exterior of the car is another factor driving revenue growth in the market. 

 

Offline Distribution Channel Leading the Market Expansion  

In 2023, the offline distribution channel, holding a revenue share of 61.33%, is anticipated to dominate sales in the global decorative films and foils market. The continued prominence of offline channels persists in mitigating the risk of product damage, particularly concerning decorative films and foils and their associated costs. Despite the growing trend of online sales, a significant portion of distribution for these products occurs through specialty stores. Producers of decorative films and foils capitalize on the personalized customer service offered by specialty stores and supermarkets. 

Moreover, the online channel holds a relatively lower market share but is expected to witness the highest segmental CAGR during the forecast period. The proliferation of e-commerce and a rise in the awareness of the benefits of online purchases, such as heavy discounts, occasional offers, and convenience, drive the growth of the online segment. Furthermore, high penetration rates are expected for online multichannel platforms, and vendors are expected to grow their online presence through their e-commerce platforms and collaborations with other e-commerce firms during the forecast period. 

 

Growing Popularity of Solar Films and Foils Creating Immense Opportunities for Vendors  

Solar control window films, blocking 90% to 95% of harmful UVA and UVB radiation, offer consumers flexibility in various shades and sizes. Adjustable thickness affects light transmission levels (3% to 70%), safeguarding vehicle interiors and extending their lifespan by preventing direct sunlight entry. The rising adoption of sun-controlled decorative films, driven by skin disease prevention needs, is augmented by adverse atmospheric conditions in regions like India, the UAE, Brazil, and Mexico. Healthcare industries increasingly use solar control films, with specialized offerings like Kling Shield’s reflective sun control window film ensuring light entry and interior visibility. The automotive sector witnesses heightened demand for heat dissipation solutions, propelling decorative film adoption. Technological advancements, notably multilayer nanotechnology, enhance product performance, driving market growth. Rapid industrialization, urbanization, and growing disposable incomes generate global demand for decorative films. Increased passenger vehicle demand, particularly in developed economies, and rising per capita incomes are expected to fuel solar control decorative film growth in the foreseeable future. 

 

Buy this Research @ https://www.arizton.com/market-reports/decorative-films-and-foils-market 

 

Post-Purchase Benefit                             

  • 1hr of free analyst discussion                            

  • 10% off on customization   

 

Key Company Profiles 

  • Eastman 

  • 3M Company 

  • LINTEC Corporation 

  • LG Hausys 

  • Madico 

  • RENOLIT 

  • Klockner Pentaplast 

  • OMNOVA Solutions 

  • Grafix Plastics 

  • Dumore Corporation 

  • Avery Dennison Corporation 

  • Peiyu Plastic Corporation 

  • ORAFOL Group 

  • Sun Process Converting, Inc. 

  • RASIK PRODUCTS PVT. LTD. 

  • Yodean Decor 

  • Decorative Films, LLC 

  • America Standard Window Films 

  • Armolan Window Films 

  • Toray Plastics 

  • Saint-Gobain Performance Plastics Corporation 

 

Market Segmentation 

Category Type 

  • Adhesive 

  • Non-adhesive 

Material Type 

  • PVC 

  • PET 

  • PP 

  • Others 

Product Type 

  • Frosted 

  • Architectural 

  • Vinyl 

  • Others 

Technology 

  • Metalized 

  • Ceramic 

  • Dyed 

  • Others 

Usage Type 

  • Indoor 

  • Outdoor 

End-user 

  • Commercial 

  • Residential 

  • Automotive 

  • Marine 

  • Others 

Distribution Channel 

  • Offline 

  • Online 

Geography 

  • North America 

  • The US 

  • Canada 

  • Europe 

  • The UK 

  • Germany 

  • France 

  • Russia 

  • Italy 

  • Spain 

  • Netherlands 

  • Belgium 

  • APAC 

  • China 

  • Japan 

  • India 

  • Australia 

  • South Korea 

  • Latin America 

  • Brazil 

  • Mexico 

  • Argentina 

  • Middle East & Africa 

  • South Africa 

  • Saudi Arabia 

  • The UAE 

  • Turkey 

 

Key Questions Answered in the Report:   

How big is the decorative films and foils market? 

What is the growth rate of the global decorative films and foils market? 

Which region dominates the global decorative films and foils market share? 

What are the significant trends in the decorative films and foils industry? 

Who are the key players in the global decorative films and foils market? 

 

Why Arizton?                      

100% Customer Satisfaction                      

24×7 availability – we are always there when you need us                      

200+ Fortune 500 Companies trust Arizton’s report                      

80% of our reports are exclusive and first in the industry                      

100% more data and analysis                      

1500+ reports published till date                       

 

About Us:                                                           

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                         

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                          

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040 /+1 302 469 0707  
Country: United States
Website: https://www.arizton.com/market-reports/decorative-films-and-foils-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Decorative Films and Foils Market to Hit USD 3.91 billion by 2029, Innovation of Solar-Powered Advancements Creating Huge Market Expansion – Arizton

Pain Management Devices Market Forecast to Grow at 21.5% CAGR from 2024 to 2031 | SkyQuest Technology

“Skyquest Technology”
Pain Management Devices Market Size, Share, Growth Analysis, By Product(Electrical Stimulators, Radiofrequency Ablation (RFA), Analgesic Infusion Pumps, and Neurostimulation), By Application(Cancer, Neuropathic Pain, Facial & Migraine, Musculoskeletal Disorder), By Region – Industry Forecast 2024-2031

Pain Management Devices Market size was valued at around USD 12.76 billion in 2022 and is expected to rise from USD 15.50 billion in 2023 to reach a value of USD 73.7 billion by 2031, at a CAGR of 21.5% over the forecast period (2024–2031).

Pain management devices are medical devices specifically designed to help control pain. These devices are intended to be used as part of a comprehensive pain management program and can provide relief for various types of pain, including chronic, acute, and postoperative pain.

Pain management devices, especially those involving implants or implantable procedures, are subject to rigorous regulatory scrutiny to ensure safety and effectiveness. Probably pain management devices will not be equally accessible in all communities due to variations in health care. Furthermore, pain management devices can be expensive, especially advanced neuromuscular implants and drug delivery systems.

Competitive Landscape of the Pain Management Devices Market

Key players and their strategies

Download a detailed overview:

https://www.skyquestt.com/sample-request/pain-management-devices-market

Medtronic Plc

Overview: Medtronic is a leading company in the pain management device market, known for its advanced neuromuscular technology.

Strategy: The Company will continue to focus on innovation, extensive clinical trials and strategic expansion of its product portfolio and market.

Recent developments: Medtronic recently launched a new spinal stimulation program and has been actively engaged in research to improve its devices.

Boston Science Corporation: Expanding Horizons

Overview: Boston Scientific is a leading competitor, offering a wide range of pain management solutions, including spinal stimulation and radiofrequency ablation programs.

Strategy: The company’s growth strategy includes product diversification, strategy, and a strong emphasis on R&D.

Recent developments: Boston Scientific is expanding its footprint worldwide and introducing several new products to address a variety of pain conditions.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/pain-management-devices-market

Analyze the Business Verticals in the Pain Management Devices Market

Overview: Muscle-modifying devices, such as spinal stimulators and peripheral nerve stimulators, are important in the management of chronic pain by modulating muscle activity. These devices are designed to conduct the electrical current specific areas of the nerve to alter pain signals and muscle pain, chronic back pain, complex regional pain syndromes etc. to provide relief to patients suffering from various conditions.

Driving Factors: Technological advances, increased prevalence of chronic pain conditions, and increased preference for non-opioid pain relievers are the major drivers of this segment.

In May 2024, the FDA has approved Medtronic’s closed-loop rechargeable spinal cord stimulator (SCS), Inceptiv, as a new treatment for chronic pain. This approval makes the SCS device the first in the market to use a closed-loop device that senses biological signals around the spine. This stimulator will automatically change the stimulation in real time and improve the treatment and life in the day-to-day activities.

In April 2024, triCure launched the cryoSPHERE+ cryoablation probe, a device designed to improve postoperative pain management. This new probe features advanced insulation technology that reduces freeze times by 25% compared to the legacy cryoSPHERE device.  

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/pain-management-devices-market

Paving the Way for Effective Relief: The Future of Pain Management Devices

The pain management devices market is poised for tremendous growth, driven by technological advances, aging population, and increasing chronic pain conditions. Innovations in tissue modification, pumping into the body, and into the analgesic system, improve the convenience and efficacyof preventive analgesia. As patient demand for non-opioid pain relievers increases, the market is likely to see expanded use of these devices. Legal assistance and payment processing is also expected to play an important role in the market expansion. Through continuous research and development, the pain management devices market is destined to provide effective, convenient and safe pain management solutions, providing a bright future for patients and healthcare professionals.

Related Reports:

3D Printing Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/pain-management-devices-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pain Management Devices Market Forecast to Grow at 21.5% CAGR from 2024 to 2031 | SkyQuest Technology

Dental Bone Graft Substitutes Market Worth $1.8 billion | MarketsandMarkets™

“Europe accounted for the second-largest share of dental bone graft substitute. The apidly aging population, leading to a higher demand for dental bone graft substitute is driving the growth of dental bone graft substitute in the European region.”
Dental Bone Graft Substitutes Market in terms of revenue was estimated to be worth $1.3 billion in 2024 and is poised to reach $1.8 billion by 2029, growing at a CAGR of 7.7% from 2024 to 2029 according to a new report by MarketsandMarkets™.

 Dental Bone Graft Substitutes Market in terms of revenue was estimated to be worth $1.3 billion in 2024 and is poised to reach $1.8 billion by 2029, growing at a CAGR of 7.7% from 2024 to 2029 according to a new report by MarketsandMarkets™.

The global population is growing older, leading to an increased demand for dental bone graft substitute also the increasing popularity of dental implants as a tooth replacement option creates a direct need for bone graft substitutes which is expected to drive the market growth. However, high material costs and surgical costs associated with hospital or clinic fees, surgeon fees, and anesthesia is expected to challenge the growth of the market.

This report divides dental bone graft substitute into four segments – type, application, mechanism, product, end user and region.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=159678690

“Based on dental bone graft substitute by end user, the hospitals segment is expected to grow at the highest CAGR during the forecast period.”

Under end user, hospital segment is forecasted to grow at the highest CAGR from 2024 to 2029., Bone grafting is frequently used in hospitals for oral and maxillofacial surgery for procedures like jaw reconstruction, alveolar ridge preservation, cleft lip and palate repair and dental implantology, when natural jawbone is insufficient for implant placement, bone grafts provide a foundation for successful implant osseointegration (fusion with bone).

“The Bio-Oss segment is expected to account for the largest share, by product in dental bone graft substitute.”

By product segment, dental bone graft substitute is segmented into Bio-Oss, osteograf, grafton and others. Bio-Oss accounts for the largest share in by product category. Bio-Oss has a long history of successful use in dental bone grafting procedures, with extensive clinical research supporting its efficacy and safety which is expected to drive the segment growth.

“The osteoconduction segment is expected to account for the largest share, by mechanism in dental bone graft substitute.”

By mechanism segment, dental bone graft substitute is segmented into bio osteoconduction, osteoinduction, osteopromotion, osteogenesis. osteoconduction accounts for the largest share in by mechanism category. Osteoconduction promotes bone regeneration at the defect site, provides a foundation for dental implant placement and supports jawbone structure and prevents collapse which is expected to drive the segment growth.

“In 2023, Europe was the region with the second largest market share in dental bone graft substitute. “

Dental bone graft substitute is segmented into five major regions, namely, North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East and Africa and GCC countries.

Europe accounted for the second-largest share of dental bone graft substitute in 2023. The apidly aging population, leading to a higher demand for dental bone graft substitute is driving the growth of dental bone graft substitute in the European region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=159678690

Dental Bone Graft Substitutes Market Dynamics:

Drivers:

  1. Rising aging population

Restraints:

  1. Stringent regulatory guidelines for medical devices

Opportunities:

  1. Growing Prevalence of Dental Disorders

Challenge:

  1. High Surgical Procedures Costs

Key Market Players of Dental Bone Graft Substitutes Industry:

Key players in dental bone graft substitute include Dentsply Sirona Inc. (US), Envista Holdings Corporation (US), JOHNSON & JOHNSON (US), Stryker Corporation (US), Medtronic, Plc (Ireland), Institut Straumann AG (Switzerland),  Zimvie Inc. (US), Henry Schein Inc. (US), RTI Surgical Holdings Inc.(US), Lifenet Health (US), Dentium (US), Geistlich Pharma AG (Switzerland), Integra Lifesciences Holdings Corporation (US), Tissue Regenix Group (UK), Kuraray Co. Ltd. (Japan), BEGO GmbH & Co. KG (Germany), Young Innovations (US), Keystone Dental (US), Novabone LLC. (US), Biotiss Biomaterials LLC (US), Collagen Matrix Inc.(US), Osteogenics Biomedical (US), Hannox International Corp.(Taiwan), Meyer Haake GMBH (Germany) and  Arora Biosurgery Ltd. (New Zealand).

A breakdown of the primary participants (supply-side) for the dental bone graft substitute market referred to for this report is provided below:

  • By Company Type: Tier 40%, Tier 35%, and Tier 25%
  • By Designation: C-level–30%, Director Level–55%, and Others–15%
  • By Region: North America–20%, Europe–15%, Asia Pacific–25%, Latin America- 10%, Middle East & Africa-30%.

Get 10% Free Customization on this Report:https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=159678690

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: Switzerland
Website: https://www.prnewswire.com/news-releases/dental-bone-graft-substitutes-market-worth-1-8-billion–marketsandmarkets-302131562.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dental Bone Graft Substitutes Market Worth $1.8 billion | MarketsandMarkets™

Wet Age-Related Macular Degeneration Pipeline 2024 | OliX Pharmaceuticals, Frontera Therapeutics, Kyowa Kirin, Boehringer Ingelheim, Clearside Biomedical, PanOptica, EyePoint Pharmaceuticals

DelveInsight’s, “Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Insight, 2024,” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the Wet Age-Related Macular Degeneration pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Wet Age-Related Macular Degeneration therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Wet Age-Related Macular Degeneration Research. Learn more about our innovative pipeline today! @ Wet Age-Related Macular Degeneration Pipeline Outlook

 

Key Takeaways from the Wet Age-Related Macular Degeneration Pipeline Report

  • August 2024:- Outlook Therapeutics Inc.:- Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT. Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
  • DelveInsight’s Wet Age-Related Macular Degeneration pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Wet Age-Related Macular Degeneration treatment.
  • The leading Wet Age-Related Macular Degeneration Companies such as OliX Pharmaceuticals, Frontera Therapeutics, Kyowa Kirin, Boehringer Ingelheim, Clearside Biomedical, PanOptica, EyePoint Pharmaceuticals, Unity Biotechnology, AngioLab, Kinarus Therapeutics, Sylentis, Mabwell (Shanghai) Bioscience, Samsung Bioepis, Sandoz, Outlook Therapeutics, Molecular Partners, Sam Chun Dang Pharm, TOT Biopharm, and others.
  • Promising Wet Age-Related Macular Degeneration Pipeline Therapies in the various stages of development include Aflibercept (Eylea, BAY86-5321), Eyp-1901, NG101 AAV gene therapy, CMAB818, Lucentis®, RC28-E, Aflibercept, Ranibizumab, SCT510A, SCD411, Aflibercept, and others.

 

Stay informed about the cutting-edge advancements in Wet Age-Related Macular Degeneration Treatments. Download for updates and be a part of the revolution in cancer care @ Wet Age-Related Macular Degeneration Clinical Trials Assessment

 

Wet Age-related Macular Degeneration Emerging Drugs

  • RGX-314: REGENXBIO

RGX-314 is a one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. RGX-314 is being developed as a potentially one-time treatment for wet AMD, diabetic retinopathy, and other additional chronic retinal conditions treated with anti-VEGF.

  • 9MW 0211: Mabwell (Shanghai) Bioscience

9MW 0211 is a recombinant anti-VEGF humanized monoclonal antibody obtained based on rabbit monoclonal antibody and humanized transformation technology, which is a category 1 therapeutic biological product. It can specifically bind to the most active VEGF-A in the VEGF family, block its binding to receptors on the surface of endothelial cells, reduce vascular permeability and block the formation and development of new blood vessels, and reduce the leakage caused by new blood vessels, so as to achieve the purpose of treating eye diseases related to neovascularization such as neovascular (wet) age-related macular degeneration. The drug is currently being evaluated in Phase II/III clinical trial to treat patients with wet-AMD.

  • SYL1801: Sylentis

SYL1801 is a chemically modified siRNA, engineered using Sylentis proprietary SirFinder, which inhibits the synthesis of Nrarp. It is administered as an eye drop solution to transcriptionally down-regulate the expression of Nrarp, a target different from those against which the usual anti-angiogenic therapies based on anti-VEGF agents are directed. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with wet AMD.

  • OLX10212: OliX Pharmaceuticals

OLX10212 is a novel cell penetrating asymmetric small interference RNA being developed by OliX Pharmaceuticals in Phase I stage of development for the treatment of wet-MAD. OLX10212 targets inflammation pathways that play a key role in the development of geographic atrophy (GA) and neovascular AMD.

 

Learn more about Wet Age-Related Macular Degeneration Drugs opportunities in our groundbreaking Wet Age-Related Macular Degeneration Research and development projects @ Wet Age-Related Macular Degeneration Unmet Needs

 

Wet Age-related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

 

Wet Age-Related Macular Degeneration Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

 

Discover the latest advancements in Wet Age-Related Macular Degeneration Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Wet Age-Related Macular Degeneration Market Drivers and Barriers, and Future Perspectives

 

Wet Age-Related Macular Degeneration Companies and Therapies

  • Neuracle Genetics Inc.: NG101 AAV gene therapy
  • RemeGen Co. Ltd:- RC28-E
  • Outlook Therapeutics Inc.:- Bevacizumab/Ranibizumab

 

Scope of the Wet Age-Related Macular Degeneration Pipeline Report

  • Coverage- Global
  • Wet Age-Related Macular Degeneration Companies- OliX Pharmaceuticals, Frontera Therapeutics, Kyowa Kirin, Boehringer Ingelheim, Clearside Biomedical, PanOptica, EyePoint Pharmaceuticals, Unity Biotechnology, AngioLab, Kinarus Therapeutics, Sylentis, Mabwell (Shanghai) Bioscience, Samsung Bioepis, Sandoz, Outlook Therapeutics, Molecular Partners, Sam Chun Dang Pharm, TOT Biopharm, and others.
  • Wet Age-Related Macular Degeneration Pipeline Therapies- Aflibercept (Eylea, BAY86-5321), Eyp-1901, NG101 AAV gene therapy, CMAB818, Lucentis®, RC28-E, Aflibercept, Ranibizumab, SCT510A, SCD411, Aflibercept, and others.
  • Wet Age-Related Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Wet Age-Related Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Wet Age-Related Macular Degeneration Pipeline on our website @ Wet Age-Related Macular Degeneration Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Wet Age-related Macular Degeneration: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Wet Age-related Macular Degeneration– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. RGX-314: REGENXBIO
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SYL1801: Sylentis
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. OLX10212: OliX Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Wet Age-related Macular Degeneration- Unmet Needs
  21. Wet Age-related Macular Degeneration- Market Drivers and Barriers
  22. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Wet Age-Related Macular Degeneration Pipeline 2024 | OliX Pharmaceuticals, Frontera Therapeutics, Kyowa Kirin, Boehringer Ingelheim, Clearside Biomedical, PanOptica, EyePoint Pharmaceuticals

Momentra Care Enhances Respite Home Care in San Diego

Momentra Care in San Diego, CA, reaffirms its commitment to supporting family caregivers through exceptional respite home care. Offering flexible care schedules and personalized attention from trained caregivers, they provide peace of mind while allowing caregivers to recharge. Visit https://momentracare.com to learn more about their compassionate respite care services designed to enhance the well-being of families in San Diego.

San Diego, CA – Momentra Care is proud to announce its continued commitment to the well-being of family members by offering exceptional respite home care in San Diego. This service aims to provide peace of mind to families through trusted San Diego caregivers, allowing family caregivers to take much-needed time for themselves.

“At Momentra Care, we understand the immense responsibility family caregivers bear. Our respite home care services are designed to ensure that while caregivers take time for self-care, their loved ones receive the highest quality of care from our dedicated team,” said Juan Sotelo, owner of Momentra Care. “We are committed to providing compassionate and professional care that meets the unique needs of each family we serve.”

Momentra Care’s respite home care services are tailored to support family caregivers by offering flexible care schedules, ensuring that their loved ones are well cared for in their absence. Whether it’s for a few hours a week or extended periods, Momentra Care’s San Diego caregivers at home are trained to provide personalized and attentive care.

The benefits of respite care are numerous, providing essential support for both caregivers and their loved ones. For caregivers, respite care offers the opportunity to recharge and avoid burnout, which is crucial for maintaining their own health and well-being. It also allows caregivers to spend quality time with other family members, attend to personal needs, or simply take a break, knowing their loved ones are in capable hands.

Family caregivers can use their free time in various fulfilling ways, such as pursuing hobbies, socializing with friends, or engaging in wellness activities like exercise or meditation. This break not only helps rejuvenate caregivers but also enhances their ability to provide better care when they return. The peace of mind that comes with knowing their loved ones are receiving top-notch care allows caregivers to truly relax and enjoy their time off.

Families in San Diego seeking reliable and compassionate respite home care services can rely on Momentra Care. The company’s approach focuses on fostering independence, providing comfort, and enhancing the overall well-being of each individual in their care. This commitment to quality care underscores the importance of supporting family caregivers and ensuring their loved ones are in safe hands.

For more information about Momentra Care and their respite home care in San Diego, please visit their website at https://momentracare.com 

About Momentra Care:

Momentra Care is a leading provider of home care services in San Diego, specializing in respite care. With a team of compassionate and skilled caregivers, Momentra Care is dedicated to enhancing the quality of life for individuals and families by offering personalized care plans that meet their unique needs. The company’s mission is to support family caregivers by providing reliable and professional home care services that promote independence and well-being.

Media Contact
Company Name: Momentra Care
Contact Person: Juan Sotelo
Email: Send Email
Phone: +1 619 292 8166
Address:8880 RIO SAN DIEGO DR STE 800
City: San Diego
State: CA
Country: United States
Website: http://www.momentracare.com

Market Leaders Strategize to Meet Escalating Demand in Research Antibodies & Reagents, More than $21.28 Billion Revenue to be Generated by 2029 – Arizton

“Research Antibodies & Reagents Market Research Report by Arizton”

According to Arizton’s latest research report, the global research antibodies & reagents market is growing at a CAGR of 8.03% 2023-2029.   

 

To Know More, Click: https://www.arizton.com/market-reports/research-antibodies-and-reagents-market 

 

Research Antibodies & Reagents Market Report Scope 

Report Attributes  

Details   

Market Size (2029)  

USD 21.28 Billion 

Market Size (2023)  

USD 13.39 Billion 

CAGR (2023-2029)  

8.03% 

Historic Year  

2020-2022 

Base Year  

2023  

Forecast Year  

2024-2029  

Market Segmentation  

Product Type, Technology, Application, End-user, and Geography 

Geographic Analysis  

North America, Europe, APAC, Latin America, and Middle East & Africa  

Market Dynamics   

  • Increase in Research Academies and Industry Collaborations 

  • Growing R&D and Research Funding for Antibodies Development 

  • Rise in Proteomics and Genomics Research 

 

The research antibodies and reagents market is vital to the global life sciences and biotechnology sectors. It serves as an essential tool for researchers and scientists across disciplines. The market is poised for growth with ongoing technological advances and the increasing demand for personalized medicine and biopharmaceutical development. However, it must address quality control and regulatory challenges to ensure continued success. As the field evolves, stakeholders should adapt to changing dynamics to remain competitive in this growing industry. Antibodies play a crucial role in diagnostic applications, including immunoassays for infectious diseases, cancer biomarkers, and companion diagnostics for personalized medicine. The market is expected to continue growing in the future. There is a growing demand for customized and personalized research antibodies and reagents to meet specific research needs. Advances in antibody engineering and reagent synthesis techniques, such as recombinant antibody technology and phage display, will improve product quality. 

 

Rise in Proteomics and Genomics Research Creating Boom in the Market 

The remarkable growth in proteomics and genomics research would not have been possible without specialized tools and reagents. Research antibodies are indispensable in these fields. They are designed to recognize specific proteins or DNA sequences, enabling scientists to pinpoint and study these molecules. These antibodies have a multitude of applications, from Western blotting and immunohistochemistry to ChIP-Seq and ELISAs, serving as critical components in a wide range of laboratory techniques. 

The fields of proteomics and genomics have witnessed an extraordinary surge in research activities and applications over the last few decades. These branches of life sciences focus on the comprehensive study of proteins and genes, respectively, and play a pivotal role in unraveling the complexities of life and disease. Rapid technological advances have made a deeper understanding of the human genome and proteome increasingly accessible. This surge in research, driven by the promise of groundbreaking discoveries and clinical applications, is proving to be a driving force behind the thriving research antibodies and reagents market. 

 

ELISA Technology to Hold the Largest Share Whereas Western Blotting to Witness the Fastest Growth Rate  

In 2023, the ELISA segment accounted for a share of 25.77% of the global research antibodies & reagents market. 

Enzyme-Linked Immunosorbent Assay (ELISA) technology is a cornerstone of the research antibodies and reagents market, it does face certain challenges. ELISA’s sensitivity and specificity can vary; continuous improvement is necessary to enhance its accuracy. ELISA assays can be costly, necessitating the development of cost-effective alternatives. Traditional ELISA assays often involve manual steps, making automation an area for improvement. 

The ability to simultaneously measure multiple analytes in a single sample is an ongoing development area. In response to these challenges, there have been innovations such as the development of microfluidic ELISA platforms, improved reagents, and digital ELISA, which enhances sensitivity and quantification. 

Western blotting technology is vital in the research antibodies and reagents market. Western blotting is a fundamental method for validating the specificity and sensitivity of antibodies. Researchers use Western blots to confirm that antibodies recognize the target proteins accurately. It enables the detection and quantification of proteins in complex biological samples, such as cell lysates, tissues, and serum. This is crucial for various research applications, including biomarker discovery, disease mechanisms, and drug development. 

 

The APAC Research Antibodies & Reagents Market to Hit $4.9 Billion by 2029 

The research antibodies and reagents market in APAC is becoming increasingly competitive. Companies need to focus on product differentiation, quality assurance, and establishing strong partnerships with local research institutions to thrive. Adherence to regulatory standards is crucial in the life sciences industry. Companies operating in the APAC market should be well-versed with local and international regulations to ensure the quality and compliance of their products. 

Enhancing awareness and providing educational resources about the benefits and applications of research antibodies and reagents is essential. Collaborations with academic institutions for training programs and workshops can contribute to market growth. Tailoring products to meet the diverse APAC market’s specific research needs and preferences is essential. Companies should understand local research trends and collaborate with researchers to develop customized solutions. 

 

Buy this Research @ https://www.arizton.com/market-reports/research-antibodies-and-reagents-market 

 

Post-Purchase Benefit                            

  • 1hr of free analyst discussion                           

  • 10% off on customization  

 

Key Company Profiles 

  • Bio-Rad Laboratories 

  • Bio-Techne 

  • Danaher 

  • F.Hoffmann La-Roche 

  • Merck KGaA 

  • Thermo Fisher Scientific 

  • Abcepta 

  • Abclonal 

  • Abnova 

  • Atlas Antibodies 

  • Aviva Systems Biology 

  • Cell Signaling Technology 

  • Cantata Bio 

  • Fujirebio 

  • GeneTex 

  • GenScript 

  • ICL 

  • Jackson ImmunoResearch 

  • MBL International 

  • Omega Bio-tek 

  • Proteintech Group 

  • RayBiotech Life 

  • ROCKLAND IMMUNOCHEMICALS 

  • Santa Cruz Biotechnology 

  • SOL Group 

  • SouthernBiotech 

 

Market Segmentation  

Product Type 

  • Reagents 

  • By Product Type 

  • Media & Sera 

  • Stains & Dyes 

  • Buffers 

  • Other 

  • Antibody 

  • By Product 

  • Primary 

  • Secondary 

  • By Form 

  • Monoclonal 

  • Polyclonal 

  • By Source 

  • Rabbit 

  • Mouse 

  • Rat 

  • Other 

  • By Research Area 

  • Oncology 

  • Infectious Diseases 

  • Immunology 

  • Neurobiology 

  • Stem Cell 

  • Other 

Technology 

  • ELISA 

  • Flow Cytometry 

  • Western Blotting 

  • Immunofluorescence 

  • Immunohistochemistry 

  • Immunoprecipitation 

  • Other 

Application 

  • Proteomics 

  • Drug Development 

  • Genomics 

End-user 

  • Academic & Research Institutes and Research Labs 

  • Pharma & Biotech Companies 

  • CROs & CDMOs 

Geography 

  • North America 

  • The US 

  • Canada 

  • Europe 

  • Germany 

  • The UK 

  • France 

  • Italy 

  • Spain 

  • Russia 

  • Netherlands 

  • APAC 

  • China 

  • Japan 

  • India 

  • South Korea 

  • Australia 

  • Latin America 

  • Brazil 

  • Mexico 

  • Argentina 

  • Colombia 

  • Middle East & Africa 

  • Turkey 

  • South Africa 

  • Saudi Arabia 

  • The UAE 

 

Key Questions Answered in the Report:  

How big is the research antibodies & reagents market? 

What is the growth rate of the global research antibodies & reagents market? 

Which region dominates the global research antibodies & reagents market share? 

What are the significant trends in the research antibodies & reagents industry? 

Who are the key players in the global research antibodies & reagents market? 

 

Why Arizton?                     

100% Customer Satisfaction                     

24×7 availability – we are always there when you need us                     

200+ Fortune 500 Companies trust Arizton’s report                     

80% of our reports are exclusive and first in the industry                     

100% more data and analysis                     

1500+ reports published till date                      

 

About Us:                                                          

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                        

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                         

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                               

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040 / +1 302 469 0707    
Country: United States
Website: https://www.arizton.com/market-reports/research-antibodies-and-reagents-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Market Leaders Strategize to Meet Escalating Demand in Research Antibodies & Reagents, More than $21.28 Billion Revenue to be Generated by 2029 – Arizton

Agrochemicals Market is Poised to Grow at a CAGR of 2.80%, Attributed to Consequent Increase in Demand for Food and Soil Degradation

“Skyquest Technology”
Agrochemicals Market Size, Share, Growth Analysis, By Crop Type, Fertilizer Type(Nitrogenous, Phosphatic, Potassic Fertilizer), Pesticide Type(Fungicides, Herbicides, Insecticides, Nematicides, Others), Mode of Application(Foliar, Fertigation, Others), and Region – Industry Forecast 2024-2031

Agrochemicals Market size was valued at USD  224.90 Billion in 2019 and is poised to grow from USD 231.20 billion in 2023 to USD 288.36 billion by 2031, at a CAGR of 2.80% during the forecast period (2024-2031).

Horticulture, floriculture, and agriculture use artificial chemicals or biological components called agrochemicals to increase crop quality and yield. Horticulture, floriculture, and agriculture use artificial chemicals or biological components called agrochemicals to increase crop quality and yield. Adjuvants, pesticides, and fertilizers are included in agrochemicals. These agrochemicals are used for specific purposes and vary on the type of plantation or crop being grown. It might be synthetic or biobased. The agrochemicals industry is growing significantly due to rise in the need for food. The population is expanding, thus, the demand for agricultural products and use of agrochemicals is increasing. This is to enhance crop yields. Consequently, to meet the need for food, agrochemicals are essential.

Download a detailed overview:

https://www.skyquestt.com/sample-request/agrochemicals-market

Tech Tools in Farming: The Role of Technology in Agrochemical Advancements

The continuous advancements in agricultural technology have brought about changes in farming techniques. As a result of the increased import and export of agricultural commodities across many geographies, especially in developing countries, new types of harmful organisms have surfaced. This has increased consumer demand for products that preserve crops using cutting-edge active chemicals. The crop protection markets in Asia is influenced by globalization of the agrochemical industry. The need for food production has increased due to fastest growth of population. As a result, prices of agrochemicals, including pesticides and herbicides are rising.

Policy Impact: Driving Forces Behind Agrochemical Adoption and Productivity

The need for agrochemicals has increased due to increased agricultural production globally, and the government has played a significant role in increasing this demand. Farmers must accept tax cuts and subsidies to support government programs. Better fertilizers are more in demand in nations where agriculture is the main industry. In these circumstances, the global agrochemicals market’s overall revenue volume is predicted to rise.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/agrochemicals-market

Companies Advancing Within the Agrochemicals Sector

  • February 2022: Adama released Timeline® FX, an enhanced cross-spectrum spring foliar herbicide for cereals. Thanks to its three complimentary active ingredients and integrated adjuvant, this product gives farmers the widest application window of any herbicide for controlling grass and broadleaf weeds for cereal crops.
  • January 2022: Yara and Lantmännen signed a business agreement in bringing fossil-free fertilizers to the market. Due to this collaboration, a commercial arrangement for green fertilizers was reached; Yara will now produce fertilizers, while Lantmännen will begin marketing them in Sweden in 2023.

 

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/agrochemicals-market

Evolution of Agrochemical Solutions

Agrochemicals enable farmers to grow crops that are higher-quality and more plentiful. The global market is extremely competitive due to the large number of local competitors. Strong fertilizers and pesticides such as fumigants, herbicides, rodenticides, insecticides, fungicides, and regulators of plant development are being pushed onto the market by manufacturers. Players are compared to one another based on a variety of factors, such as services, innovation, sustainability, and company reputation, in addition to product quality, pricing, and availability.

Related Reports:

Cannabis Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/agrochemicals-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Agrochemicals Market is Poised to Grow at a CAGR of 2.80%, Attributed to Consequent Increase in Demand for Food and Soil Degradation

The Ultimate Guide to Stretching Shoes: Why Medipaq’s Wooden Shoe Stretcher is the Best Choice

Medipaq’s Wooden Shoe Stretcher: The Complete Package

When it comes to comfort and foot health, ensuring your shoes fit perfectly is crucial. Tight shoes can cause discomfort, blisters, and long-term foot problems. Luckily, there’s an easy solution: a high-quality wooden shoe stretcher. Among the best options available, Medipaq’s wooden shoe stretcher stands out for its exceptional design and added features, making it the perfect choice for stretching your shoes effectively and comfortably.

Why Choose a Wooden Shoe Stretcher?

There are many types of shoe stretchers on the market, but not all are created equal. While plastic models may seem like a cheaper alternative, they often fall short in durability and effectiveness. Wooden shoe stretchers, especially those made from premium pine like Medipaq’s, offer a reliable, long-lasting solution that preserves the shape and integrity of your shoes over time.

Plastic stretchers can crack or lose their form after just a few uses, but wooden stretchers provide a consistent, even stretch. Medipaq’s wooden shoe stretcher, crafted from quality pine, is designed to deliver superior results, making it a smart investment for anyone who needs a lasting solution.

Medipaq’s Wooden Shoe Stretcher: What’s Included?

Medipaq offers shoe stretchers tailored for both men and women. The men’s version fits US sizes 8-13, and the women’s model fits US sizes 4-9. These stretchers feature a 2-way mechanism that allows you to easily adjust both the length and width of your shoes, ensuring a perfect fit. The large adjustment wheel and sturdy design make the stretching process simple and effective.

One of the key benefits of Medipaq’s product is the inclusion of cedar balls, which naturally deodorize your shoes, keeping them fresh. Additionally, multiple shapers are included, allowing you to target specific areas of your shoes, such as around bunions or other pressure points, to maximize comfort.

Extra Accessories for an Enhanced Experience

Medipaq goes above and beyond by including several useful accessories. In addition to the shoe stretchers and cedar balls, you’ll also receive a shoehorn, which makes slipping on your newly stretched shoes easier, and a drawstring bag for convenient storage, keeping your closet organized.

Conclusion: The Best Shoe Stretcher for the Perfect Fit

When it comes to stretching your shoes, choosing a high-quality shoe stretcher is essential for achieving the best results. Medipaq’s wooden shoe stretcher stands out for its durability, ease of use, and thoughtful features like cedar balls and specific shapers. These benefits, combined with the included shoehorn and storage bag, make Medipaq’s product the top choice for improving the fit and comfort of your shoes.

Don’t compromise on comfort. If your shoes are feeling tight, Medipaq’s shoe stretcher is the ideal solution. For men’s sizes, explore the product here, or if you need a women’s stretcher, you can find it here. Invest in Medipaq today and experience the difference.

Media Contact
Company Name: Medipaq
Contact Person: Sim @ Medipaq
Email: Send Email
Country: United States
Website: https://www.amazon.com/Medipaq-Wooden-Shoe-Stretchers-GentS/dp/B002DQ08DI/